One-and-done bargain? Several multimillion-dollar gene therapies are on the market, and companies justify their cost by saying that they are “one-and-done” cures or long-term treatments for expensive illnesses. But such drugs should not be considered a bargain, says Hastings Center research scholar Michael Gusmano. “There’s no question that these gene therapies are going to be expensive he told Wired. “The question is: At what level will payers push back and simply refuse to cover them.” Read the Wired article.

Burden of proof. In 18 states, laws prohibit transgender students from participating in sports consistent with their gender identity, but any advantage that transgender athletes may have depends on many factors, said Hastings Center President Emeritus Tom Murray. “There’s no good reason to limit the participation of transgender athletes where male athletes don’t have an advantage over women,” such as sailing, he said in an interview with Leaps magazine. “The burden of proof rests on those who want to restrict participation by transgender athletes. They must show that in this sport, at this level of competition, transgender athletes have a conspicuous advantage.” Read the Leaps article.

Last week, Murray moderated an event, “Genetic Advantages in Sports: When Do They Count as ‘Doping’?” Watch the event.